Across TCGA pan-cancer cohorts, RNU6-1026P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RNU6-1026P’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RNU6-1026P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-1026P is over-expressed in tumor.

STAD and BLCA are the cancer types where RNU6-1026P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1026P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	+0.223	.012	4	view →
BLCA	All	All	+0.407	.045	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RNU6-1026P RNA expression & survival · all RNU6-1026P data types